|1.||Akhondzadeh, Shahin: 2 articles (12/2008 - 06/2003)|
|2.||Zhang, Min: 2 articles (02/2007 - 09/2003)|
|3.||Nurse, Colin A: 2 articles (02/2007 - 09/2003)|
|4.||Johnson, Bankole A: 2 articles (01/2004 - 09/2003)|
|5.||Sugimoto, Y: 2 articles (12/2001 - 10/2001)|
|6.||Yamada, J: 2 articles (12/2001 - 10/2001)|
|7.||Parks, Clinton R: 1 article (12/2015)|
|8.||Burton, Frank H: 1 article (12/2015)|
|9.||Bittner, Katie C: 1 article (12/2015)|
|10.||McGrath, Michael J: 1 article (12/2015)|
|1.||Schizophrenia (Dementia Praecox)
11/01/2000 - "These results suggest that ritanserin has a intrinsic dopaminergic effect which may help to explain its reported improvement on mood, cognition and negative symptoms of schizophrenia."
12/12/2008 - "The present study indicates ritanserin as a potential adjunctive treatment strategy for the negative symptoms of schizophrenia. "
12/12/2008 - "Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study."
02/01/1994 - "The effect of the selective serotonin-2 antagonist ritanserin was investigated in an open study of patients with schizophrenia. "
02/01/1994 - "An open clinical and biochemical study of ritanserin in acute patients with schizophrenia."
|2.||Parkinsonian Disorders (Parkinsonism)
01/01/1986 - "Open pilot trial of ritanserin in parkinsonism."
01/01/1989 - "The stimulatory effect of ritanserin on midbrain DA systems might contribute to some of its clinical effects, such as improvement of mood, drive and motivation as well as its therapeutic actions in parkinsonism and type II schizophrenia."
12/01/1990 - "The results confirm previous observations of the therapeutic efficacy of ritanserin on neuroleptic-induced parkinsonism, and support the hypothesis that serotonin influences extrapyramidal physiopathology."
02/01/2010 - "The many interactions between the serotoninergic and dopaminergic systems require the implementation of clinical studies on the complex motor impact of serotoninergic treatments, which may aggravate the parkinsonian syndrome while improving gait (as is the case with paroxetine and ritanserin). "
12/01/1990 - "The Mindham Rating Scale was used to assess symptoms of parkinsonism; at week 3, ritanserin was superior to orphenadrine (p less than 0.03) and to placebo (p less than 0.01). "
01/01/1988 - "Ritanserin, a selective and potent serotonin-2 antagonist, is effective in the treatment of a variety of syndromes related to anxiety and depression, including dysthymic disorder. "
04/01/1991 - "Thirty patients suffering from dysthymic disorder participated in a 6-week double-blind trial comparing ritanserin 10 mg and placebo. "
04/01/1991 - "5-HT2 receptor antagonism in dysthymic disorder: a double-blind placebo-controlled study with ritanserin."
12/01/1993 - "Fifty outpatients with dysthymic disorder (DSM-III) were divided by double-blind randomized assignment into three groups given ritanserin, imipramine, and placebo, respectively. "
12/01/1993 - "Ritanserin, imipramine, and placebo in the treatment of dysthymic disorder."
05/01/1997 - "8-OH-DPAT (0.1 mg/kg, SC) given 2.5 h after, and ritanserin (0.63 and 1.25 mg/kg, IP), given 15 min prior to HAL, significantly reduced the neuroleptic-induced catalepsy. "
11/01/1996 - "It was found that ritanserin (2 mg kg-1 s.c.) enhanced the raclopride (0.1 mg kg-1 s.c.)-induced suppression of CAR without affecting raclopride-induced catalepsy at either maximal (4 mg kg-1 s.c.) or submaximal (0.2 mg kg-1 s.c.) doses. "
12/27/1995 - "The effects of DOI on raclopride-induced catalepsy were fully antagonized by pretreatment with the 5-HT2A/C receptor antagonist, ritanserin (2 mg kg-1 s.c.). "
04/27/1988 - "Stereotaxic injection of SCH 23390 (D-1 antagonist), but not water or ritanserin (5-HT antagonist), into all parts of the caudate-putamen, elicited an immediate and often long-lasting catalepsy in 79% of rats. "
10/01/2003 - "CLOZ and the 5-HT2A/2C antagonists ritanserin, RS102221 and SB242084 were more effective in antagonizing HP than HP+Delta9-THC-induced catalepsy.7 HP and CLOZ failed to inhibit in vitro [3H]CP-55,940 binding, while Delta9-THC and SR141716A did not show an appreciable affinity for the D2 receptor. "
|5.||Psychomotor Agitation (Akathisia)
01/01/1990 - "We report first results of a single-blind trial of ritanserin in the treatment of neuroleptic-induced akathisia. "
02/01/1994 - "Ritanserin was well tolerated and no extrapyramidal symptoms or akathisia were seen. "
03/01/1992 - "3. Discontinuation of Ritanserin led to a recurrence of akathisia."
03/01/1992 - "The effect of ritanserin on treatment-resistant neuroleptic induced akathisia: case reports."
01/01/1990 - "Treatment of neuroleptic induced akathisia with the 5-HT2 antagonist ritanserin."
|1.||Serotonin (5 Hydroxytryptamine)
|2.||Serotonin 5-HT2 Receptor Antagonists
|6.||5-HT2A Serotonin Receptor (5 HT2A Receptor)
|8.||Antipsychotic Agents (Antipsychotics)
|2.||Drug Therapy (Chemotherapy)